Registry-listed formulations

motesanib diphosphate · mesh:C000625785

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

7 source entries across 6 studies. This list may not include all unresolved or historical entries.

AMG 706Registry intervention
Linked study entry; product equivalence not established
View study and source
AMG 706Registry intervention
Linked study entry; product equivalence not established
View study and source
AMG 706Registry intervention
Linked study entry; product equivalence not established
View study and source
AMG 706Registry intervention
Linked study entry; product equivalence not established
View study and source
AMG 706Registry intervention
Linked study entry; product equivalence not established
View study and source
AMG 706Registry intervention
Molecular identity unconfirmed
View study and source
AMG 706Registry intervention
Molecular identity unconfirmed
View study and source

Success Metrics

Clinical Success Rate

50.0%

Based on 3 completed trials

Completion Rate

38%(3/8)

Active Trials

0(0%)

Results Posted

100%(3 trials)

Terminated

5(56%)

Phase Distribution

Phase 1/2

11%

Phase 1

22%

Phase 3

11%

Phase 2

56%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution9 total trials

Phase 1Safety & dosage

2(22.2%)

Phase 1/2Combined phases

1(11.1%)

Phase 2Efficacy & side effects

5(55.6%)

Phase 3Large-scale testing

1(11.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

37.5%

3 of 8 finished

Non-Completion Rate

62.5%

5 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(3)

Terminated(5)

Other(1)

Detailed Status

Terminated5

Completed3

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

50.0%

Most Advanced

Phase 1/2

Trials by Phase

Phase 12 (22.2%)

Phase 1/21 (11.1%)

Phase 25 (55.6%)

Phase 31 (11.1%)

Trials by Status

unknown111%

terminated556%

completed333%

Recent Activity

0 active trials

Showing 5 of 9

completedphase_2

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

NCT00427349

terminatedphase_2

AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT00574951

terminatedphase_2

A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC

NCT00369070

completedphase_1

To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.

NCT00861419

completedphase_1_2

Study to Evaluate Motesanib With or Without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT00094835

View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials

NCT00427349Phase 2

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Completed

NCT00574951Phase 2

AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Terminated

NCT00369070Phase 2

A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC

Terminated

NCT00861419Phase 1

To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.

Completed

NCT00094835Phase 1/2

Study to Evaluate Motesanib With or Without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Completed

NCT00356681Phase 2

A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer

Terminated

NCT00360867Phase 2

An Open Label Treatment Extension Study of AMG 706

Terminated

NCT00460317Phase 3

MONET1-MOtesanib NSCLC Efficacy and Tolerability Study

Terminated

NCT00324597Phase 1

AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma